Latest ASX stocks to be hit by a broker downgrade

The market is extending its rally following the US presidential elections, but brokers have downgraded some ASX stocks to the naughty list.
The post Latest ASX stocks to be hit by a broker downgrade appeared first on Motley Fool Australia. –

Downgrade ASX stocks

The market is extending its rally following the US presidential elections, but brokers have downgraded some ASX stocks to the naughty list.

The S&P/ASX 200 Index (Index:^AXJO) jumped a further 1.6% as we head into the close with every sector trading in the black.

But one stock that’s heading in the opposite direction is the Ramsay Health Care Limited Fully Paid Ord. Shrs (ASX: RHC) share price.

Second wave prompts downgrade of ASX stocks

Shares in the hospital operator tanked 2.9% to $67.48 at the time of writing after Credit Suisse downgraded the stock to “neutral” from “outperform”.

You can blame COVID‐19 for the underperformance, even though the pandemic should be less of a concern with a potential vaccine just around the corner.

“While we continue to believe that RHC will be a beneficiary of a volume tailwind post COVID‐19, there remains significant near‐ term earnings pressure for RHC’s offshore divisions with rising COVID‐19 cases in Europe,” warned Credit Suisse.

Increased hospital admission rates for COVID cases will hamper Ramsay’s ability to undertake more profitable elective surgeries.

It looks as though Ramsay’s facilities in France and the UK will take a hit due to a significant second wave of the disease.

Credit Suisse’s price target on the Ramsay share price is $70 a share.

Longer than expected recovery from pandemic

Meanwhile, the CSL Limited (ASX: CSL) share price was also downgraded, although that didn’t stop it from rising 0.8% to $307.06 in late trade.

Citigroup cut its rating on the blood treatment company to “neutral” from “buy” as it believes that COVID-19 is impacting on its operations.

“In the last few weeks, we had quarterly results from key competitors and suppliers including Takeda, Grifols, and Haemonetics,” said Citi.

“All noted the plasma product demand remains unchanged, however collections have been impacted by COVID-19.”

The broker believes that plasma collection will only return to normal levels in Jan 2021 compared to its earlier prediction of October 2020.

Citi’s 12-mopnth price target on the CSL share price is $320 a share.

New tech casualty from COVID rotation

News of the possible COVID vaccine triggered a large sell-off in tech stocks. It also gave Bell Potter a reason to chop its recommendation on the Macquarie Telecom Group Ltd. (ASX: MAQ) share price to “hold” from “buy”.

“With its focus on Data Centres (DCs) and the cloud, MAQ too has seen a large share price rise over the past year,” said the broker.

“While we view MAQ’s rise as justified on account of its long-term DC and cloud growth outlook, with an anticipated rotation towards more cyclical names as a US and Australian re-opening gains greater focus and COVID fear subsidies, MAQ’s shares may see some near-term selling pressure.”

Bell Potter’s 12-month price target on the stock is $52.40 a share.

Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

BrenLau owns shares of CSL don Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Latest ASX stocks to be hit by a broker downgrade appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!